Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal Ozurdex to prevent recurrent vitreous hemorrhage after vitrectomy for proliferative diabetic retinopathy
2011-003297-81Phase 2Active
- Sponsor
- St. Eriks Eye Hospital
- Start
- Jul 2011
- Modality
- Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial of ozurdex in proliferative diabetic retinopathy (PDR) (2 arms), sponsored by St. Eriks Eye Hospital. Primary endpoint: Need for second pars plana vitrectomy due to re-bleeding within 12 months. Started Jul 2011; status: active.
02
Drugs
ozurdex
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on 2011-003297-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003297-81.